{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T16:27:08Z","timestamp":1788798428054,"version":"build-2803163510"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2010,5,1]],"date-time":"2010-05-01T00:00:00Z","timestamp":1272672000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Urology"],"published-print":{"date-parts":[[2010,5]]},"DOI":"10.1016\/j.juro.2009.12.105","type":"journal-article","created":{"date-parts":[[2010,3,18]],"date-time":"2010-03-18T04:25:09Z","timestamp":1268886309000},"page":"1738-1743","source":"Crossref","is-referenced-by-count":15,"title":["Loss of Heterozygosis on IFN-\u03b1 Locus is a Prognostic Indicator of Bacillus Calmette-Guerin Response for Nonmuscle Invasive Bladder Cancer"],"prefix":"10.1097","volume":"183","author":[{"given":"Tommaso","family":"Cai","sequence":"first","affiliation":[{"name":"Department of Urology, University of Florence, Florence, Italy"},{"name":"Department of Critical Care Medicine and Surgery (Clinical Pharmacology Unit), University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Nesi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Oncology, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Dal Canto","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Galliano","family":"Tinacci","sequence":"additional","affiliation":[{"name":"Department of Pathology, Santa Maria Annunziata Hospital, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Mondaini","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Piazzini","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierangelo","family":"Geppetti","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine and Surgery (Clinical Pharmacology Unit), University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Bartoletti","sequence":"additional","affiliation":[{"name":"Department of Urology, University of Florence, Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"10.1016\/j.juro.2009.12.105_bib1","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib2","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1097\/01.ju.0000173919.28835.aa","article-title":"Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose?","volume":"174","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib3","first-page":"1790","article-title":"Management of bacillus Calmette-Guerin (BCG) refractory superficial bladder cancer: results with intravesical BCG and interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Can J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib4","doi-asserted-by":"crossref","first-page":"335","DOI":"10.2165\/00002512-200118050-00004","article-title":"Medical management of patients with refractory carcinoma in situ of the bladder","volume":"18","author":"Kim","year":"2001","journal-title":"Drugs Aging"},{"key":"10.1016\/j.juro.2009.12.105_bib5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0022-5347(17)37452-9","article-title":"Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-up","volume":"147","author":"Herr","year":"1992","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.juro.2009.12.105_bib7","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.eururo.2006.01.017","article-title":"Management of BCG failures in superficial bladder cancer: a review","volume":"49","author":"Witjes","year":"2006","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib8","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2005.03.021","article-title":"Cystectomy in patients with high risk superficial bladder tumours who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor","volume":"48","author":"Huguet","year":"2005","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cancergencyto.2008.02.015","article-title":"Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guerin immunotherapy in bladder cancer","volume":"184","author":"Ahirwar","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.juro.2009.12.105_bib10","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.ju.0000136446.37840.0a","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer","volume":"172","author":"O'Donnell","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib11","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1097\/01.ju.0000131944.52354.63","article-title":"Mechanism of bacillus Calmette-Guerin mediated natural killer cell activation","volume":"172","author":"Suttman","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0302-2838(01)00026-4","article-title":"Guidelines on bladder cancer","volume":"41","author":"Oosterlinck","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib13","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1097\/01.ju.0000062605.92268.c6","article-title":"Defining bacillus Calmette-Guerin refractory superficial bladder tumors","volume":"169","author":"Herr","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib14","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/MOU.0b013e32830b86a9","article-title":"Follow-up of nonmuscle invasive transitional cell carcinoma of the bladder: how and how often?","volume":"18","author":"Schmidbauer","year":"2008","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib15","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1016\/S0022-5347(06)00283-7","article-title":"Multiplex polymerase chain reaction in microsatellite analysis urine sediment cells","volume":"175","author":"Bartoletti","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib16","first-page":"531","article-title":"Early diagnosis and monitoring of superficial transitional cell carcinoma by microsatellite analysis on urine sediment","volume":"13","author":"Bartoletti","year":"2005","journal-title":"Oncol Rep"},{"key":"10.1016\/j.juro.2009.12.105_bib17","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","article-title":"Maintenance BCG immunotherapy for recurrent Ta, T1 and Tis transitional cell carcinoma of the bladder: a randomized prospective Southwest Oncology Group study","volume":"163","author":"Lamm","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib18","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0302-2838(03)00048-4","article-title":"Do prognostic parameters of remission versus relapse after bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy exist?","volume":"43","author":"Saint","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib19","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)66983-2","article-title":"Urinary interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin","volume":"164","author":"Thalmann","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib20","first-page":"2840","article-title":"Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder","volume":"7","author":"Slaton","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.juro.2009.12.105_bib21","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1007\/s00262-009-0673-z","article-title":"Recombinant bacillus Calmette-Guerin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro","volume":"58","author":"Liu","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.juro.2009.12.105_bib22","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1097\/01.ju.0000059681.67567.12","article-title":"The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guerin","volume":"169","author":"Bilen","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1046\/j.1464-410X.2002.02722.x","article-title":"Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Gu\u00e9rin with a reduced dose of 27 mg in superficial bladder cancer","volume":"89","author":"Mart\u00ednez-Pi\u00f1eiro","year":"2002","journal-title":"BJU Int"},{"key":"10.1016\/j.juro.2009.12.105_bib24","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S0022-5347(01)65674-X","article-title":"Clinicopathologic evaluation of repeated courses of intravesical bacillus Calmette-Guerin instillation for preventing recurrence of initially resistant superficial bladder cancer","volume":"156","author":"Okamura","year":"1996","journal-title":"J Urol"},{"key":"10.1016\/j.juro.2009.12.105_bib25","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1200\/JCO.1996.14.6.1778","article-title":"Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression","volume":"14","author":"Kaempfer","year":"1996","journal-title":"J Clin Oncol"}],"container-title":["Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534709034041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022534709034041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.jurology.com\/doi\/pdf\/10.1016\/j.juro.2009.12.105","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,28]],"date-time":"2022-04-28T21:52:05Z","timestamp":1651182725000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jurology.com\/doi\/10.1016\/j.juro.2009.12.105"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,5]]}},"alternative-id":["10.1016\/j.juro.2009.12.105"],"URL":"https:\/\/doi.org\/10.1016\/j.juro.2009.12.105","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.4242963.4039062","asserted-by":"object"}]},"ISSN":["0022-5347","1527-3792"],"issn-type":[{"value":"0022-5347","type":"print"},{"value":"1527-3792","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5]]}}}